AbbVie's public policy engagement is guided by the following principles:
AbbVie is committed to transparency and is guided by our Code of Business Conduct in all public policy engagement.
AbbVie pursues activities that shape policies to benefit patients, with a focus on improving patient access to new medical advances.
Our Federal Government Affairs office in Washington, D.C. is responsible for advocacy activities with the U.S. Congress and the federal government. Advocacy at the U.S. state level is managed by our State Government Affairs function. AbbVie also hires outside firms that can provide expertise on our key policy issues. AbbVie does not currently make direct expenditures towards U.S. federal or state grassroots lobbying communications to the general public.
In the United States, in compliance with the Lobbying Disclosure Act, AbbVie will file a quarterly report that includes: (i) total federal lobbying expenditures, (ii) the name of the specific piece of legislation or subject that was the topic of communication, (iii) disclosure of AbbVie individuals who lobbied on behalf of AbbVie, and (iv) identification of the legislative body or executive branch that was contacted. This report incorporates expenses associated with lobbying the federal government, including our Federal Government Affairs office and the portion of trade association dues associated with federal lobbying.